Published in Biotech Law Weekly, August 26th, 2005
All newly manufactured product will be labeled with multi-dose labels. In the meantime, any existing vials with the single dose label will be considered as multi-dose products by the Centers for Medicaid and Medicare Services (CMS).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.